AN INTERVENTIONAL PHASE 2/3, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS
Latest Information Update: 10 Oct 2024
At a glance
- Drugs Sisunatovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Pfizer
- 07 Oct 2024 Status changed from active, no longer recruiting to discontinued. (Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study.)
- 19 Sep 2024 Planned End Date changed from 21 Mar 2026 to 30 Sep 2024.
- 19 Sep 2024 Planned primary completion date changed from 21 Mar 2026 to 30 Sep 2024.